BioNTech SE ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $3.4B+18.3% YoYTTM through 31 Dec 2025
Net Income -$1.3BTTM through 31 Dec 2025
Free Cash Flow $330MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 77.6% |
| Operating Margin | -49.0% |
| Net Margin | -39.6% |
Returns
-5.9%ROE
-5.2%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio7.54x
Net Debt-$14.8Bnet cash position
Cash & Equivalents$7.7B
Quality Metrics
Piotroski F-Score3 / 9
FCF Margin9.8%
Earnings-Beat Rate0.0%
Multi-Year Trend
Diluted EPSFY2025: $-4.70
Dividend
$2.11Per share, FY20220.00%Yield
Capital Allocation
Capex Intensity5.2%
Segment Performance
No segment data available.
Financials converted at 0.8513 from EUR.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.